Verition Fund Management
MLYS icon

Verition Fund Management’s Mineralys Therapeutics MLYS Stock Holding History

Verition Fund Management’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$677K Buy
+25,000
New +$733K ﹤0.01% 1479

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $231M AUM 83.19% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Verition Fund Management's MLYS Position: Q1 2026 in Review

Verition Fund Management increased its Mineralys Therapeutics (MLYS) stake by 13% in Q1 2026, buying an estimated $331K and bringing the position to 95,122 shares worth $2.58M. The position accounts for 0.02% of the portfolio, ranked #891.

Verition Fund Management first reported a position in MLYS in Q2 2024 and has held it in 5 quarters since. The position peaked at $3.04M in Q4 2025. 214 funds tracked by Wall St. Rank hold MLYS as of Q1 2026.

  • Verition Fund Management held 95,122 shares of Mineralys Therapeutics worth $2.58M as of Q1 2026.
  • Verition Fund Management bought 11,282 Mineralys Therapeutics shares in Q1 2026, an estimated $331K.
  • Mineralys Therapeutics made up 0.02% of Verition Fund Management's portfolio in Q1 2026, its #891 holding.
  • Verition Fund Management first reported a position in Mineralys Therapeutics in Q2 2024 and has held it in 5 quarters since.
  • Verition Fund Management's Mineralys Therapeutics position peaked at $3.04M in Q4 2025.
  • 214 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q1 2026.

Based on Verition Fund Management's 13F filing for Q1 2026, filed 15 May 2026.